Trial
NCT02864290
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
ASP1235
Why stopped
Study was terminated due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-23